Ureteral stent related symptoms: A comparative study.


Journal

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
ISSN: 2282-4197
Titre abrégé: Arch Ital Urol Androl
Pays: Italy
ID NLM: 9308247

Informations de publication

Date de publication:
04 Mar 2024
Historique:
received: 25 12 2023
accepted: 29 12 2023
medline: 5 3 2024
pubmed: 5 3 2024
entrez: 5 3 2024
Statut: aheadofprint

Résumé

In urology, ureteral stents are used to treat obstructive diseases. Hematuria (54%), fever, discomfort, and lower urinary system symptoms are the predominant symptoms related to ureteral stent. This article links stent symptoms to double-j width and length, as well as patient's height, weight, and body mass index (BMI). Ureteric Stent Symptoms Questionnaire (USSQ) was used to measure ureteral stent symptoms at 1st and 4th week of stent in situ as well as the 4th week after pigtail removal. A 200-patient prospective study, where patients were allocated into four groups following ureteral stent insertion depending on the stent characteristics. Those groups were: 4.8 Fr./26 cm (Group A), 4.8 Fr./28 cm (Group B), 6 Fr/26 cm (Group C), and 6 Fr/28 cm (Group D). Men comprised 53.5% of 200 patients. Participants had an average age of 49 ± 15.5 years, height of 175 ± 8.94 cm, and BMI of 23.8 ± 7.6 cm. The laboratory results were identical between groups. At the first and fourth week, groups had similar urine symptoms, pain severity, health status and occupational activities. The difference in pain location was statistically significant. Group A had 82.4% renal back pain in the first week, whereas Group B had 68.8%, Group C 31.3% and Group D 62.5 (p = 0.04). At the fourth week, 64.7% of Group A patients reported kidney front pain, compared to 100% of Group B, 93.3% of Group C, and 100% of Group D (p = 0.04). There was statistical significance in the sexual activity of the patients. 24.4% of Group C patients stopped sexual activity before stent installation, compared to 10.6%, 8.3%, and 6.4% of the other groups (p = 0.03). A moderate percentage of patients had active sexual activity at week 4 (Group A: 7.8%, Group B: 5.8%, Group C: 8.2%, Group D: 4.1%), p = 0.83. In multivariate analysis, urinary catheter group, age, weight, height, and BMI did not significantly affect urine index score (UIS), pain index score (PIS), general health (GH), quality of work (QW), and quality of sex (QS). Despite various attempts to establish the best ureteral stent, the effect of double-j stent physical features on stent-related symptoms remained unknown. No verdict is conceivable without adequate empirical data.

Sections du résumé

BACKGROUND BACKGROUND
In urology, ureteral stents are used to treat obstructive diseases. Hematuria (54%), fever, discomfort, and lower urinary system symptoms are the predominant symptoms related to ureteral stent.
AIM OBJECTIVE
This article links stent symptoms to double-j width and length, as well as patient's height, weight, and body mass index (BMI). Ureteric Stent Symptoms Questionnaire (USSQ) was used to measure ureteral stent symptoms at 1st and 4th week of stent in situ as well as the 4th week after pigtail removal.
METHODS METHODS
A 200-patient prospective study, where patients were allocated into four groups following ureteral stent insertion depending on the stent characteristics. Those groups were: 4.8 Fr./26 cm (Group A), 4.8 Fr./28 cm (Group B), 6 Fr/26 cm (Group C), and 6 Fr/28 cm (Group D).
RESULTS RESULTS
Men comprised 53.5% of 200 patients. Participants had an average age of 49 ± 15.5 years, height of 175 ± 8.94 cm, and BMI of 23.8 ± 7.6 cm. The laboratory results were identical between groups. At the first and fourth week, groups had similar urine symptoms, pain severity, health status and occupational activities. The difference in pain location was statistically significant. Group A had 82.4% renal back pain in the first week, whereas Group B had 68.8%, Group C 31.3% and Group D 62.5 (p = 0.04). At the fourth week, 64.7% of Group A patients reported kidney front pain, compared to 100% of Group B, 93.3% of Group C, and 100% of Group D (p = 0.04). There was statistical significance in the sexual activity of the patients. 24.4% of Group C patients stopped sexual activity before stent installation, compared to 10.6%, 8.3%, and 6.4% of the other groups (p = 0.03). A moderate percentage of patients had active sexual activity at week 4 (Group A: 7.8%, Group B: 5.8%, Group C: 8.2%, Group D: 4.1%), p = 0.83. In multivariate analysis, urinary catheter group, age, weight, height, and BMI did not significantly affect urine index score (UIS), pain index score (PIS), general health (GH), quality of work (QW), and quality of sex (QS).
CONCLUSIONS CONCLUSIONS
Despite various attempts to establish the best ureteral stent, the effect of double-j stent physical features on stent-related symptoms remained unknown. No verdict is conceivable without adequate empirical data.

Identifiants

pubmed: 38441229
doi: 10.4081/aiua.2024.12231
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12231

Auteurs

Themistoklis Ch Bellos (TC)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. bellos.themistoklis@gmail.com.

Ioannis S Manolitsis (IS)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. giannismanolit@gmail.com.

Stamatios N Katsimperis (SN)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. stamk1992@gmail.com.

Panagiotis A Angelopoulos (PA)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. angelopoulospanag@gmail.com.

Sotirios G Kapsalos-Dedes (SG)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. kapsalos13@gmail.com.

Panagiotis K Deligiannis (PK)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. panosdlg@gmail.com.

Lazaros I Tzelves (LI)

1st Department of Urology, Metropolitan General, Cholargos. lazarostzelves@gmail.com.

Nikolaos A Kostakopoulos (NA)

1st Department of Urology, Metropolitan General, Cholargos. nikostakop@gmail.com.

Iraklis C Mitsogiannis (IC)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. imitsog@med.uoa.gr.

Ioannis M Varkarakis (IM)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. medvark3@yahoo.com.

Athanasios G Papatsoris (AG)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. agpapatsoris@yahoo.gr.

Andreas A Skolarikos (AA)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. andskol@yahoo.com.

Charalampos N Deliveliotis (CN)

2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens. chdeliveli@gmail.com.

Classifications MeSH